New Clinical Trial Tests Bone Disease Drug to Protect Beta Cells in Early Type 1 Diabetes

City of Hope, a top research center based in Los Angeles known for diabetes and other life-threatening illnesses, is launching a Phase 1-2 clinical trial with a novel approach. Rather than developing an entirely new drug, researchers are investigating whether denosumab—a medication already approved by the FDA for osteoporosis—might offer benefits for people in the early stages of Type 1 diabetes.

The timing of this research is significant. Early intervention, shortly after diagnosis, represents a critical window where the immune system is actively attacking the insulin-producing beta cells in the pancreas. The goal is to understand whether this existing medication could help protect or preserve these cells during this vulnerable period.

Denosumab is a monoclonal antibody—a type of protein designed to target specific parts of the immune system. While it has been used successfully to strengthen bone and treat osteoporosis, researchers want to understand whether its mechanism of action might also help preserve beta cell function in people with recently diagnosed Type 1 diabetes.

By studying denosumab in this new context, researchers hope to gather data on safety and effectiveness. The Phase 1-2 design allows the team to evaluate both how well the drug is tolerated and whether it shows promise in slowing beta cell loss.

The trial is currently enrolling adults between the ages of 18 and 50 who have been recently diagnosed with Type 1 diabetes. If you meet these criteria and are interested in learning more about participation, City of Hope can provide detailed information about eligibility, what the study involves, and what to expect.

Clinical trials are how researchers test whether new (or newly applied) treatments work safely and effectively. A Phase 1-2 trial is an early stage of testing, designed to evaluate safety and gather initial evidence of benefit. Results from this trial will help determine whether larger, more extensive studies are warranted.

Participating in a clinical trial means contributing to the scientific understanding of Type 1 diabetes while potentially accessing an investigational treatment. However, it is important to understand that enrollment in a trial is a research commitment, and outcomes are not guaranteed for individual participants.

Origin: YouTube / The Sugar Science (Video report). Evidence: Video report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.